AMGN

SEC source: 0001127602-14-004375 · form4.xml · nonDerivative · entry 1

Balachandran Madhavan · CIK 0001555508 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,152

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/31/2016, 1/31/2017 and 1/31/2018, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 875 RSUs which fully vest on 4/26/2014; 3,015 RSUs which vest in one installment of 1,485 on 4/25/2014 and one installment of 1,530 on 4/25/2015; 2,512 RSUs which vest in three installments of 828, 829 and 855 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 26,634 RSUs which vest in two equal installments of 8,789 each on 7/31/2014 and 7/31/2015 and one installment of 9,056 on 7/31/2016; 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017; and 4,707 RSUs which vest in two equal installments of 1,553 each on 1/31/2016 and 1/31/2017 and one installment of 1,601 on 1/31/2018. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 932 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-14-004379 · form4.xml · nonDerivative · entry 1

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,040

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/31/2016, 1/31/2017 and 1/31/2018, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 4,500 RSUs which fully vest on 4/26/2014; 14,070 RSUs which vest in one installment of 6,930 on 4/25/2014 and one installment of 7,140 on 4/25/2015; 20,938 RSUs which vest in three installments of 6,909, 6,910 and 7,119 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 18,693 RSUs which vest in three installments of 6,168, 6,169 and 6,356 on 1/28/2015, 1/28/2016 and 1/28/2017, respectively; and 15,132 RSUs which vest in three installments of 4,993, 4,994 and 5,145 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 1,016 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-14-004380 · form4.xml · nonDerivative · entry 1

Harper Sean E · CIK 0001541946 · EVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,439

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/31/2016, 1/31/2017 and 1/31/2018, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,150 RSUs which fully vest on 4/26/2014; 25,000 RSUs which fully vest on 12/31/2014; 4,020 RSUs which vest in one installment of 1,980 on 4/25/2014 and one installment of 2,040 on 4/25/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017; and 5,044 RSUs which vest in three installments of 1,664, 1,665 and 1,715 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 415 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-14-004381 · form4.xml · nonDerivative · entry 1

HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,402

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/31/2016, 1/31/2017 and 1/31/2018, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 16,699 RSUs which fully vest on 3/2/2014; 7,239 RSUs which vest in one installment on 3/2/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017; and 5,044 RSUs which vest in three installments of 1,664, 1,665 and 1,715 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 415 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-14-004382 · form4.xml · nonDerivative · entry 1

Michael A Kelly · CIK 0001335311 · Acting CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,576

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in two equal installments on 6/30/2014 and 6/30/2015.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 329 RSUs which vest on 4/26/2014; 1,001 RSUs which vest in one installment of 493 on 4/25/2014 and one installment of 508 on 4/25/2015; 1,200 RSUs which vest in two equal annual installments of 396 each on 4/27/2014 and 4/27/2015 and one installment of 408 on 4/27/2016; 780 RSUs which vest in two equal installments of 257 each on 4/26/2015 and 4/26/2016 and one installment of 266 on 4/27/2017; and 8,406 RSUs which vest in two equal installments of 4,203 each on 6/30/2014 and 6/30/2015. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 49 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share interest.

SEC source: 0001127602-14-004390 · form4.xml · nonDerivative · entry 1

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,275

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/31/2016, 1/31/2017 and 1/31/2018, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 132 RSUs which fully vest on 4/26/2014; 1,000 RSUs which fully vest on 10/28/2014; 1,001 RSUs which vest in two installments of 493 and 508 on 4/25/2014 and 4/25/2015, respectively; 1,200 RSUs which vest in two equal installments of 396 each on 4/27/2014 and 4/27/2015 and one installment of 408 on 4/27/2016; 5,420 RSUs which vest in three installments of 1,788, 1,789 and 1,843 on 10/26/2014, 10/26/2015 and 10/26/2016, respectively; 2,103 RSUs which vest in three installments of 693, 694 and 716 on 1/28/2015, 1/28/2016 and 1/28/2017, respectively; and 1,092 RSUs which vest in two equal installments of 360 on 1/31/2016 and 1/31/2017 and one installment of 372 on 1/31/2018. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 199 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-14-004396 · form4.xml · nonDerivative · entry 1

MCNAMEE BRIAN M · CIK 0001183885 · EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,691

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/31/2016, 1/31/2017 and 1/31/2018, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,450 RSUs which fully vest on 4/26/2014; 22,081 RSUs which fully vest on 12/31/2014; 5,025 RSUs which vest in one installment of 2,475 on 4/25/2014 and one installment of 2,550 on 4/25/2015; 4,466 RSUs which vest in three installments of 1,473, 1,474 and 1,519 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 4,439 RSUs which vest in three installments of 1,464, 1,465 and 1,510 on 1/28/2015, 1/28/2016 and 1/28/2017, respectively; 11,176 RSUs which vest in two equal installments of 3,688 each on 10/25/2014 and 10/25/2015 and one installment of 3,800 on 10/25/2016; and 4,707 RSUs which vest in two equal installments of 1,553 on 1/31/2016 and 1/31/2017 and one installment of 1,601 on 1/31/2018. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 271 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-14-004399 · form4.xml · nonDerivative · entry 1

SCOTT DAVID J · CIK 0001145154 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,053

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/31/2016, 1/31/2017 and 1/31/2018, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,450 RSUs which fully vest on 4/26/2014; 22,081 RSUs which fully vest on 12/31/2014; 7,504 RSUs which vest in one installment of 3,696 on 4/25/2014 and one installment of 3,808 on 4/25/2015; 6,141 RSUs which vest in three installments of 2,026, 2,027 and 2,088 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 5,374 RSUs which vest in two equal installments of 1,773 each on 1/28/2015 and 1/28/2016 and one installment of 1,828 on 1/28/2017; and 3,362 RSUs which vest in two equal installments of 1,109 on 1/31/2016 and 1/31/2017 and one installment of 1,144 on 1/31/2018. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 296 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-14-004402 · form4.xml · nonDerivative · entry 1

Tross Stuart A · CIK 0001589641 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,892

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/31/2016, 1/31/2017 and 1/31/2018, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 362 RSUs which fully vest on 4/26/2014; 1,197 RSUs which vest in one installment of 589 on 4/25/2014 and one installment of 608 on 4/25/2015; 1,320 RSUs which vest in three installments of 435, 436 and 449 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 13,958 RSUs which fully vest on 9/1/2014; 982 RSUs which vest in two equal installments of 324 each on 4/26/2015 and 4/26/2016 and one installment of 334 on 4/26/2017; 3,180 RSUs which vest in two equal installments of 1,049 each on 10/25/2015 and 10/25/2016 and one installment of 1,082 on 10/25/2017; and 1,681 RSUs which vest in three installments of 554, 555 and 572 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 518 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-029954 · form4.xml · nonDerivative · entry 1

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,146

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 132 RSUs which fully vest on 4/26/2014; 1,000 RSUs which fully vest on 10/28/2014; 1,001 RSUs which vest in two installments of 493 and 508 on 4/25/2014 and 4/25/2015, respectively; 1,200 RSUs which vest in two equal installments of 396 each on 4/27/2014 and 4/27/2015 and one installment of 408 on 4/27/2016; 5,420 RSUs which vest in three installments of 1,788, 1,789 and 1,843 on 10/26/2014, 10/26/2015 and 10/26/2016, respectively and 2,103 RSUs which vest in three installments of 693, 694 and 716 on 1/28/2015, 1/28/2016 and 1/28/2017, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 162 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-029956 · form4.xml · nonDerivative · entry 1

Peacock Jonathan M · CIK 0001500241 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,414

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 25,000 RSUs which fully vest on 10/28/2014; 10,586 RSUs which vest in one installment of 5,214 on 4/25/2014 and one installment of 5,372 on 4/25/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 347 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-029945 · form4.xml · nonDerivative · entry 1

Garland Greg C. · CIK 0001503107 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 429

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vested imediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

SEC source: 0001127602-13-029947 · form4.xml · nonDerivative · entry 1

Tross Stuart A · CIK 0001589641 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,128

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 10/25/2015, 10/25/2016 and 10/26/2017, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 362 RSUs which fully vest on 4/26/2014; 1,197 RSUs which vest in one installment of 589 on 4/25/2014 and one installment of 608 on 4/25/2015; 1,320 RSUs which vest in three installments of 435, 436 and 449 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 13,958 RSUs which fully vest on 9/1/2014; 982 RSUs which vest in two equal installments of 324 each on 4/26/2015 and 4/26/2016 and one installment of 334 on 4/26/2017 and 3,180 RSUs which vest in two equal installments of 1,049 each on 10/25/2015 and 10/25/2016 and one installment of 1,082 on 10/25/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 435 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-029949 · form4.xml · nonDerivative · entry 1

MCNAMEE BRIAN M · CIK 0001183885 · EVP

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,900

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 10/25/2014, 10/25/2015 and 10/25/2016, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,450 RSUs which fully vest on 4/26/2014; 22,081 RSUs which fully vest on 12/31/2014; 5,025 RSUs which vest in one installment of 2,475 on 4/25/2014 and one installment of 2,550 on 4/25/2015; 4,466 RSUs which vest in three installments of 1,473, 1,474 and 1,519 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 4,439 RSUs which vest in three installments of 1,464, 1,465 and 1,510 on 1/28/2015, 1/28/2016 and 1/28/2017, respectively; and 11,176 which vest in two equal installments of 3,688 each on 10/25/2014 and 10/25/2015 and one installment of 3,800 on 10/25/2016. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 187 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-026729 · form4.xml · derivative · entry 5

Balachandran Madhavan · CIK 0001555508 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 18,000 shares

Expires 2020-04-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-026729 · form4.xml · nonDerivative · entry 4

Balachandran Madhavan · CIK 0001555508 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Indirect · By Family Trust

Disclosed balance after: 34,851

F4 · price: The price reported is an average price. The prices ranged from $112.66 to $112.90 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer.

SEC source: 0001127602-13-026729 · form4.xml · nonDerivative · entry 3

Balachandran Madhavan · CIK 0001555508 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,133

F1 · kind: These shares are being transferred to the reporting person's Family Trust.

F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 875 RSUs which fully vest on 4/26/2014; 3,015 RSUs which vest in one installment of 1,485 on 4/25/2014 and one installment of 1,530 on 4/25/2015; 2,512 RSUs which vest in three installments of 828, 829 and 855 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 26,634 RSUs which vest in two equal installments of 8,789 each on 7/31/2014 and 7/31/2015 and one installment of 9,056 on 7/31/2016; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 620 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-026729 · form4.xml · nonDerivative · entry 2

Balachandran Madhavan · CIK 0001555508 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Indirect · By Family Trust

Disclosed balance after: 52,851

F1 · kind: These shares are being transferred to the reporting person's Family Trust.

SEC source: 0001127602-13-026729 · form4.xml · nonDerivative · entry 1

Balachandran Madhavan · CIK 0001555508 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,133

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-026332 · form4.xml · nonDerivative · entry 2

BALTIMORE DAVID · CIK 0001185858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,879

SEC source: 0001127602-13-026334 · form4.xml · nonDerivative · entry 1

PELHAM JUDITH C · CIK 0001185287 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,939

SEC source: 0001127602-13-026332 · form4.xml · nonDerivative · entry 1

BALTIMORE DAVID · CIK 0001185858 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,789

F1 · price: The price reported is an average price. The prices ranged from $109.61 to $109.70 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer.

SEC source: 0001127602-13-018291 · form4.xml · derivative · entry 7

Dittrich Thomas J.W. · CIK 0001491654 · VP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,020

Underlying: Common Stock · 1,980 shares

Expires 2021-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-018291 · form4.xml · derivative · entry 6

Dittrich Thomas J.W. · CIK 0001491654 · VP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,150

Underlying: Common Stock · 2,150 shares

Expires 2020-04-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-018291 · form4.xml · derivative · entry 5

Dittrich Thomas J.W. · CIK 0001491654 · VP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,000 shares

Expires 2016-04-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-018291 · form4.xml · nonDerivative · entry 4

Dittrich Thomas J.W. · CIK 0001491654 · VP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,733

F1 · price: The price reported is an average price. The prices ranged from $104.7601 to $104.83 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer.

F2 · balance_after: The shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 308 RSUs which fully vest on 4/26/2014; 1,149 RSUs which vest in annual installments of 566 and 583 on 4/25/2014 and 4/25/2015, respectively; 1,400 RSUs which vest in two equal installments of 462 each on 4/27/2014 and 4/27/2015 and one installment of 476 on 4/27/2016; and 942 RSUs which vest in annual installments of 310, 311 and 321 on 4/26/2015, 4/26/2016 and 4/26/2017, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 26 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan, as amended and restated, and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-018291 · form4.xml · nonDerivative · entry 3

Dittrich Thomas J.W. · CIK 0001491654 · VP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,863

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-018291 · form4.xml · nonDerivative · entry 2

Dittrich Thomas J.W. · CIK 0001491654 · VP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,883

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-018291 · form4.xml · nonDerivative · entry 1

Dittrich Thomas J.W. · CIK 0001491654 · VP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,733

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017759 · form4.xml · derivative · entry 5

Balachandran Madhavan · CIK 0001555508 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,000 shares

Expires 2016-04-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017759 · form4.xml · nonDerivative · entry 4

Balachandran Madhavan · CIK 0001555508 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Indirect · By Family Trust

Disclosed balance after: 34,851

F4 · price: The price reported is an average price. The prices ranged from $103.18 to $103.42 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer.

SEC source: 0001127602-13-017759 · form4.xml · nonDerivative · entry 3

Balachandran Madhavan · CIK 0001555508 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,956

F1 · kind: These shares are being transferred to the reporting person's Family Trust.

F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 875 RSUs which fully vest on 4/26/2014; 3,015 RSUs which vest in one installment of 1,485 on 4/25/2014 and one installment of 1,530 on 4/25/2015; 2,512 RSUs which vest in three installments of 828, 829 and 855 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 26,634 RSUs which vest in two equal installments of 8,789 each on 7/31/2014 and 7/31/2015 and one installment of 9,056 on 7/31/2016; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 443 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-017759 · form4.xml · nonDerivative · entry 2

Balachandran Madhavan · CIK 0001555508 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Indirect · By Family Trust

Disclosed balance after: 40,851

F1 · kind: These shares are being transferred to the reporting person's Family Trust.

SEC source: 0001127602-13-017759 · form4.xml · nonDerivative · entry 1

Balachandran Madhavan · CIK 0001555508 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,956

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017602 · form4.xml · derivative · entry 6

HENDERSON REBECCA M · CIK 0001254748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2021-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017602 · form4.xml · derivative · entry 5

HENDERSON REBECCA M · CIK 0001254748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

Underlying: Common Stock · 2,000 shares

Expires 2020-04-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017602 · form4.xml · nonDerivative · entry 4

HENDERSON REBECCA M · CIK 0001254748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,477

F2 · price: The price reported is an average price. The prices ranged from $105.8301 to $105.85 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer.

F3 · balance_after: These shares include 93 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-017602 · form4.xml · nonDerivative · entry 3

HENDERSON REBECCA M · CIK 0001254748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,898

F1 · price: The price reported is an average price. The prices ranged from $105.67 to $105.75 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer.

SEC source: 0001127602-13-017602 · form4.xml · nonDerivative · entry 2

HENDERSON REBECCA M · CIK 0001254748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,898

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017602 · form4.xml · nonDerivative · entry 1

HENDERSON REBECCA M · CIK 0001254748 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,898

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017468 · form4.xml · derivative · entry 8

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,501

Underlying: Common Stock · 1,724 shares

Expires 2021-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017468 · form4.xml · derivative · entry 7

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 920

Underlying: Common Stock · 920 shares

Expires 2020-04-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017468 · form4.xml · derivative · entry 6

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 900 shares

Expires 2016-04-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017468 · form4.xml · nonDerivative · entry 4

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,442

F1 · price: The price reported is an average price. The prices ranged from $104.999 to $105.0415 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 132 RSUs which fully vest on 4/26/2014; 2,000 RSUs which vest in two equal annual installments of 1,000 each commencing 10/28/2013; 1,001 RSUs which vest in two installments of 493 and 508 on 4/25/2014 and 4/25/2015, respectively; 1,200 RSUs which vest in two equal installments of 396 each on 4/27/2014 and 4/27/2015 and one installment of 408 on 4/27/2016; 5,420 RSUs which vest in three installments of 1,788, 1,789 and 1,843 on 10/26/2014, 10/26/2015 and 10/26/2016, respectively; and 2,103 RSUs which vest in three installments of 693, 694 and 716 on 1/28/2015, 1/28/2016 and 1/28/2017, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 82 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-13-017468 · form4.xml · nonDerivative · entry 3

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,986

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017468 · form4.xml · nonDerivative · entry 2

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,262

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017468 · form4.xml · nonDerivative · entry 1

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,342

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017189 · form4.xml · derivative · entry 5

BIONDI FRANK · CIK 0001032669 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2016-04-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017189 · form4.xml · derivative · entry 4

BIONDI FRANK · CIK 0001032669 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2014-04-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-13-017189 · form4.xml · nonDerivative · entry 3

BIONDI FRANK · CIK 0001032669 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,780

F1 · price: The price reported is an average price. The prices ranged from $108.25 to $108.64 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F2 · balance_after: These shares include 352 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.